Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:TG 17:1_18:1_20:2)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST003988 AN006569 Lipid and cell cycling perturbations driven by the HDAC inhibitor romidepsin render liver cancer vulnerable to RTK targeting and immunologically active Cultured cells Human Cancer CNRS LC-MS
ST003637 AN005973 lomitapide effects on lipidomics Pancreas Human Cancer Pennsylvania State University LC-MS
ST003528 AN005795 Lipidomics profiling of livers from Alb-Cre +/- SART-/- (KO) versus age matched wild type WT mouse littermates to characterize progression to hepatic steatosis and hepatocellular carcinoma Liver Mouse Cancer University of Utah LC-MS
ST003341 AN005475 Untargeted Lipidomic Profiling of Canine Cancer Cell Lines Cultured cells Dog Cancer Kojin Therapeutics, Inc. LC-MS
ST003222 AN005283 A small molecule macrophage migration inhibitory factor agonist ameliorates age-related myocardial intolerance to ischemia-reperfusion insults via metabolic regulation - Part 1 Heart Mouse Ischemia University of Mississippi Medical Center LC-MS
ST003220 AN005280 Obesity, sex, and depot drive distinct lipid profiles in murine white adipose tissue Adipose tissue Mouse Obesity University of Utah LC-MS
ST002787 AN004534 Metabolomic analysis of gut metabolites in colorectal cancer patients: correlation with disease development and outcome Feces Human Cancer Wuhan University of Science and Technology LC-MS
  logo